Replimune Group, Inc. (REPL)
15.50
-0.10
(-0.64%)
USD |
NASDAQ |
Aug 28, 16:00
15.44
-0.06
(-0.39%)
After-Hours: 20:00
Replimune Group Free Cash Flow : -280.54M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -280.54M |
| March 31, 2026 | -284.57M |
| December 31, 2025 | -283.27M |
| September 30, 2025 | -269.69M |
| June 30, 2025 | -227.86M |
| March 31, 2025 | -198.94M |
| December 31, 2024 | -191.98M |
| September 30, 2024 | -188.31M |
| June 30, 2024 | -192.93M |
| March 31, 2024 | -191.13M |
| December 31, 2023 | -176.27M |
| September 30, 2023 | -156.57M |
| June 30, 2023 | -144.83M |
| March 31, 2023 | -130.32M |
| December 31, 2022 | -120.98M |
| Date | Value |
|---|---|
| September 30, 2022 | -110.65M |
| June 30, 2022 | -100.43M |
| March 31, 2022 | -84.52M |
| December 31, 2021 | -77.70M |
| September 30, 2021 | -72.50M |
| June 30, 2021 | -66.36M |
| March 31, 2021 | -63.78M |
| December 31, 2020 | -59.48M |
| September 30, 2020 | -65.67M |
| June 30, 2020 | -69.17M |
| March 31, 2020 | -67.09M |
| December 31, 2019 | -62.37M |
| September 30, 2019 | -49.32M |
| June 30, 2019 | -34.95M |
| March 31, 2019 | -27.98M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Moderna, Inc. | -1.244B |
| Kalaris Therapeutics, Inc. | -45.63M |
| Arrowhead Pharmaceuticals, Inc. | -75.11M |
| Oncolytics Biotech, Inc. | -26.53M |
| Sangamo Therapeutics, Inc. | -90.46M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -75.73M |
| Cash from Investing (Quarterly) | 49.99M |
| Cash from Financing (Quarterly) | 0.80M |
| Free Cash Flow Per Share (Quarterly) | -0.7819 |
| Free Cash Flow to Equity (Quarterly) | -76.12M |
| Free Cash Flow to Firm (Quarterly) | -72.66M |
| Free Cash Flow Yield | -19.91% |